Assessing sirtuin expression in endometrial carcinoma and nonneoplastic endometrium

Oncotarget

Volumn 7, Issue 2, 2016, Pages 1144-1154

  Bartosch, Carla ^a,b   Monteiro Reis, Sara ^a   Almeida Rios, Diogo ^a   Vieira, Renata ^a   Castro, Armando ^c   Moutinho, Manuel ^c   Rodrigues, Marta ^c   Graça, Inês ^a   Lopes, José Manuel ^b,c,d   Jerónimo, Carmen ^a,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c Universidade do Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Endometrial carcinoma; Endometrium; Pathology Section; SIRT1; SIRT7; Sirtuin

Indexed keywords

MESSENGER RNA; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; MITOCHONDRIAL PROTEIN; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SIRT3 PROTEIN, HUMAN; SIRT4 PROTEIN, HUMAN; SIRT5 PROTEIN, HUMAN; SIRT6 PROTEIN, HUMAN; SIRT7 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIRTUIN GENE; ENDOMETRIUM TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOCHONDRIAL PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUINS;

EID: 84957642755     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6691     Document Type: Article

References (33)

1. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012; 120:383-397.
2. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI and Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014; 45:28-36.
3. Choi JE and Mostoslavsky R. Sirtuins, metabolism, and DNA repair. Current opinion in genetics & development. 2014; 26C:24-32.
4. Bosch-Presegue L and Vaquero A. The dual role of sirtuins in cancer. Genes & cancer. 2011; 2:648-662. doi: 10.1177/1947601911417862
5. de Oliveira MV, Andrade JM, Paraiso AF and Santos SH. Sirtuins and cancer: new insights and cell signaling. Cancer investigation. 2013; 31:645-653.
6. Roth M and Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2014; 33:1609-1620.
7. Sebastian C, Satterstrom FK, Haigis MC and Mostoslavsky R. From sirtuin biology to human diseases: an update. The Journal of biological chemistry. 2012; 287:42444-42452.
8. Lin L, Zheng X, Qiu C, Dongol S, Lv Q, Jiang J, Kong B and Wang C. SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis. Oncology reports. 2014; 32:2831-2835.
9. Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H and Shiozawa T. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Laboratory investigation; a journal of technical methods and pathology. 2015; 95:1363-1373.
10. Taguchi A, Wada-Hiraike O, Kawana K, Koga K, Yamashita A, Shirane A, Urata Y, Kozuma S, Osuga Y and Fujii T. Resveratrol suppresses inflammatory responses in endometrial stromal cells derived from endometriosis: a possible role of the sirtuin 1 pathway. The journal of obstetrics and gynaecology research. 2014; 40:770-778.
11. Shirane A, Wada-Hiraike O, Tanikawa M, Seiki T, Hiraike H, Miyamoto Y, Sone K, Hirano M, Oishi H, Oda K, Kawana K, Nakagawa S, Osuga Y, Fujii T, Yano T, Kozuma S, et al. Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression. Biochemical and biophysical research communications. 2012; 424:604-610.
12. Matias-Guiu X and Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013; 62:111-123.
13. Moore RL, Dai Y and Faller DV. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol. 2012; 213:37-48.
14. Moore RL and Faller DV. SIRT1 represses estrogensignaling, ligand-independent ERalpha-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol. 2013; 216:273-285.
15. van Leeuwen I and Lain S. Sirtuins and p53. Advances in cancer research. 2009; 102:171-195.
16. Gonfloni S, Iannizzotto V, Maiani E, Bellusci G, Ciccone S and Diederich M. P53 and Sirt1: routes of metabolism and genome stability. Biochemical pharmacology. 2014; 92:149-156.
17. Fang Y and Nicholl MB. A dual role for sirtuin 1 in tumorigenesis. Current pharmaceutical design. 2014; 20:2634-2636.
18. Stunkel W and Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. Journal of biomolecular screening. 2011; 16:1153-1169.
19. Kiran S, Anwar T, Kiran M and Ramakrishna G. Sirtuin 7 in cell proliferation, stress and disease: Rise of the Seventh Sirtuin! Cellular signalling. 2015; 27:673-682.
20. Kim W and Kim JE. SIRT7 an emerging sirtuin: deciphering newer roles. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2013; 64:531-534.
21. Kiran S, Oddi V and Ramakrishna G. Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response. Experimental cell research. 2015; 331:123-141.
22. Malik S, Villanova L, Tanaka S, Aonuma M, Roy N, Berber E, Pollack JR, Michishita-Kioi E and Chua KF. SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Scientific reports. 2015; 5:9841.
23. Guo H-y, Zhang Y-l, Li Z-h, Bing-juan Z and Guo S-q. Expression and significance of SIRT1 and Survivin in endometrial carcinoma. Chinese Journal of Clinical and Experimental Pathology. 2012-11.
24. Marc C. (2008). A expressão da enzima sirtuina 1 (SIRT1) no câncer de endométrio (Master Thesis Dissertation): Universidade Católica do Rio Grande do Sul).
25. Guo SW. The endometrial epigenome and its response to steroid hormones. Mol Cell Endocrinol. 2012; 358:185-196.
26. Munro SK, Farquhar CM, Mitchell MD and Ponnampalam AP. Epigenetic regulation of endometrium during the menstrual cycle. Mol Hum Reprod. 2010; 16:297-310.
27. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, et al. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer biology & therapy. 2011; 12:447-457.
28. de Sousa Abreu R, Penalva LO, Marcotte EM and Vogel C. Global signatures of protein and mRNA expression levels. Molecular bioSystems. 2009; 5:1512-1526.
29. Velez-Bermudez IC and Schmidt W. The conundrum of discordant protein and mRNA expression. Are plants special? Frontiers in plant science. 2014; 5:619.
30. Altmae S, Esteban FJ, Stavreus-Evers A, Simon C, Giudice L, Lessey BA, Horcajadas JA, Macklon NS, D'Hooghe T, Campoy C, Fauser BC, Salamonsen LA and Salumets A. Guidelines for the design, analysis and interpretation of 'omics' data: focus on human endometrium. Human reproduction update. 2014; 20:12-28.
31. Hu J, Jing H and Lin H. Sirtuin inhibitors as anticancer agents. Future medicinal chemistry. 2014; 6:945-966.
32. Harvey JM, Clark GM, Osborne CK and Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17:1474-1481.
33. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, To TV, Qian Z, Love RR and Allred DC. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004; 17:1545-1554.